Nivolumab is a type of immunotherapy medication that is often used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer, among others [1]. According to the drug's label, nivolumab is typically administered intravenously over a period of 30 minutes every two weeks [2]. This dosing schedule is considered one treatment cycle.

It is important to note that the frequency of nivolumab administration may vary depending on the specific type of cancer being treated, the patient's overall health, and other factors. Therefore, it is essential to follow the dosing schedule prescribed by the patient's healthcare provider.

In summary, nivolumab is typically given every two weeks, and each administration takes around 30 minutes. However, the frequency of administration may vary depending on individual circumstances.

Sources:

1. National Cancer Institute. (2021). Nivolumab. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>.
2. Bristol-Myers Squibb. (2021). Opdivo (nivolumab) Prescribing Information. Retrieved from <https://www.bms.com/content/dam/Global/healthcare/us/downloads/pi/opdivo-pi.pdf>.
3. DrugPatentWatch. (2021). Nivolumab (Opdivo) Patent Expiration & Generics. Retrieved from <https://www.drugpatentwatch.com/patent-expiration/nivolumab-opdivo>.